Overview of antiviral medications used in ophthalmology
Related content
As eye health professionals, we are fortunate to have a number of antiviral medications available in our armoury to treat a range of ophthalmic viral infections. This article provides an overview of what antiviral agents are available for these conditions, detailing their regimen and evidence that supports their use.
Ophthalmic viral infections, particularly herpes simplex keratitis, have been at the forefront of the development of antiviral medications.
The discovery of the first targeted antiviral agent, in common with penicillin (the first antibiotic), owes much to serendipity. In 1959, William Prusoff developed idoxuridine (IDU) as a potential systemic anti-cancer agent. Idoxuridine proved to be too toxic as a systemic agent; however, its mechanism of action – selectively blocking DNA synthesis – proved to be a successful strategy in the topical treatment of herpes simplex virus (HSV), a DNA virus.1
By 1962, Herbert Kaufman had introduced idoxuridine (IDU) to the world as the first antiviral drug to successfully treat a human viral infection: herpes simplex keratitis.2 For the next decade, idoxuridine was the treatment of choice for epithelial herpes simplex keratitis. However, this was not perfect as it was frequently associated with toxicity, including superficial punctate keratopathy, chemical conjunctivitis, punctal occlusion and occasional serious hypersensitivity reactions. Idoxuridine was also unable to penetrate the corneal epithelium to treat stromal or endothelial keratitis.
With the advent of aciclovir in 1982, most herpetic ophthalmic infections became treatable, including those caused by herpes zoster.3 Since then, a number of newer antivirals with similar mechanisms of action have been developed, including ganciclovir, famciclovir, valaciclovir and valganciclovir, which work in a variety of ways to inhibit the synthesis of viral DNA and thereby stop viral replication. The addition of foscarnet, which acts as DNA polymerase inhibitor, has enabled ophthalmologists to add cytomegalovirus (CMV) retinitis to the list of treatable ophthalmic viral infections. However, despite a number of attempts and potential agents, there has been limited progress in developing antiviral treatment for adenovirus.
This article provides a summary of the current ophthalmic antiviral agents that are available to treat anterior and posterior segment viral infections.
Antivirals acting on anterior segment viral infections
Herpes simplex epithelial keratitis
Herpes simplex epithelial keratitis can be treated effectively with either topical aciclovir, ganciclovir or trifluridine, as detailed below (Table 1).
The choice of agent will depend on local availability, cost and patient factors.
Oral treatment may be preferable in patients who have ocular surface disease or a poor tear film.
Avoid systemic treatment in patients known to have poor renal function.
Vidarabine 3% ointment has been withdrawn from UK and US markets, but it may still be an option in some low- and middle-income countries. It can be used 5 times a day until the epithelium has healed.
Table 1 Antiviral treatment for herpes simplex epithelial keratitis
| Drug | Dose / regimen | Comment |
|---|---|---|
| Topical aciclovir (ACV) | Aciclovir 3% ointment, five times a day for seven days, then three times a day for seven days4 | Specific for viral-infected cells only; not available in USA and some supply issues elsewhere Resistance may be increasing in immunocompromised patients (10%)5 |
| Systemic aciclovir (ACV) | Aciclovir 400 mg orally, five times a day for 7–10 days4 | As effective as topical aciclovir6; toxicity is rare but requires normal renal function |
| Topical ganciclovir (GCV) | Ganciclovir 0.15%, 5 times daily until the ulcer has healed, then three times a day for seven days4,7 | Increasing usage in UK and Europe due to aciclovir supply issues; as good as topical aciclovir for herpes simplex epithelial keratitis |
| Topical trifluridine (TFT) | Trifluridine 1% solution, 4–8 times a day4,8 | First-line therapy in the USA; as effective as topical acyclovir |
| Topical idoxuridine (IDU) | Idoxuridine 0.5% ointment or IDU 1% solution, five times a day1,4 | First topical antiviral; usage superseded by aciclovir, ganciclovir and trifluridine |
Herpes simplex stromal keratitis
Topical steroids in combination with either topical trifluridine OR topical aciclovir OR systemic aciclovir is better than treatment with antivirals alone (Table 2).
There may be some benefit of adding oral aciclovir to a course of topical steroids and topical anti-viral (trifluridine or aciclovir) for HSV-1 iritis.
At present there is little evidence for the use of ganciclovir 0.15% in the treatment of herpes simplex keratitis in combination with topical corticosteroids, and there are no randomised controlled trials comparing its efficacy to aciclovir or trifluridine. Despite this, it is likely to be of clinical value if alternatives are not available or tolerated.
Table 2 Antiviral treatment options for herpes simplex stromal keratitis. Note that these are all in addition to topical corticosteroids
| Drug | Dose / regimen | Comment |
|---|---|---|
| Topical aciclovir | Aciclovir 3% ointment, five times a day whilst using topical corticosteroids | Useful as topical antiviral cover when using topical steroid. As effective as systemic aciclovir in conjunction with topical steroids for herpes simplex keratitis6 |
| Systemic aciclovir | Aciclovir 400 mg orally, five times a day for ten weeks9,10 | No additional benefit when added to topical trifluridine and topical corticosteroids for herpes simplex keratitis.9,10 There may be some benefit of adding oral aciclovir to topical trifluridine and topical corticosteroids in cases of HSV-1 iritis, although the study did not complete enrolment11 As effective as topical aciclovir in conjunction with topical steroids for herpes simplex keratitis6 |
| Topical trifluridine | Trifluridine 1% 4–8 times a day for 3 weeks9,10 | Useful as topical antiviral cover when treating herpes simplex keratitis with topical corticosteroids |
Prophylaxis / prevention strategies against recurrent HSV ocular infections
There is strong evidence from the Herpes Eye Disease II (HEDS II) study12 that prophylactic aciclovir 400 mg twice daily reduces the recurrence of potentially blinding herpes simplex stromal keratitis with a relative risk reduction of 50% (Table 3).
It is important to measure renal function on an annual basis for patients who are on prophylactic aciclovir.
Table 3 Antiviral prophylaxis for the prevention of re-activation of HSV ocular infections
| Drug | Dose / regimen | Comment |
|---|---|---|
| Systemic aciclovir | Aciclovir 400 mg orally twice a day | There is strong evidence12 that the use of prophylactic systemic aciclovir reduces the recurrence of: Any form of ocular HSV infection (19% aciclovir vs. 32% control; p < 0.001) Herpes simplex keratitis specifically (14% aciclovir vs. 28% control; p < 0.005) |
Herpes zoster ophthalmicus (varicella zoster virus)
Oral aciclovir 800 mg five times a day for seven days remains the most widely used, affordable and available treatment for herpes zoster. It is important to start this as soon as possible; there is limited evidence of its efficacy if started more than 72 hours after the rash develops for non-ocular involvement (Table 4).
Topical antivirals (aciclovir or ganciclovir) may have a supplementary role in the presence of dendritic or pseudo-dendritic keratitis but should not be used on their own.
Topical corticosteroids should be used in the presence of stromal keratitis or iritis, and can be started in the presence of pseudo-dendrites.
Newer oral antivirals such as valaciclovir or famciclovir have better bioavailability and dosing regimes, but availability and cost remain barriers to their use globally.
Table 4 Antiviral treatment options for herpes zoster ophthalmicus (caused by varicella zoster virus)
| Drug | Dose / regimen | Comments and evidence for use |
|---|---|---|
| Systemic aciclovir | Aciclovir 800 mg orally five times a day for seven days |
|
| Topical aciclovir | Aciclovir 3% ointment, five times a day for seven days, then twice a day until dendrites have resolved | Use in the presence of dendritic keratitis but only in addition to systemic antiviral treatment. Add a topical steroid if there is stromal disease or keratitis15 |
| Topical ganciclovir | Ganciclovir 0.15%, five times a day until the ulcer has healed | Use in the presence of dendritic keratitis only in addition to systemic antiviral treatment. Add a topical steroid if there is stromal disease or keratitis |
| Systemic valaciclovir | 1 g orally three times a day for seven days | Alternative to aciclovir. Higher serum concentrations following oral administration, due to better bioavailability, means more convenient dosing (3 times a day vs 5 times a day). Potentially better than aciclovir in reducing acute pain16 |
| Systemic famciclovir | 500 mg orally three times a day for seven days | Alternative treatment options to aciclovir. Higher serum concentrations following oral administration, due to better bioavailability, means more convenient dosing (3 times a day vs 5 times a day). Potentially better than aciclovir in reducing acute pain17 |
Adenovirus ocular infections
There is currently no licensed antiviral agent for the treatment of adenoviral infections. However, a recent phase 2 randomised-controlled trial suggests benefit in using a combination of povidone-iodine 0.6% and dexamethasone 0.1% (four times a day to both eyes for five days).18 The follow-up period for this study was short (only 12 days). The combination treatment is not currently available, nor licenced. The effect of the topical steroid treatment on intraocular pressure also has to be considered.19
Povidone-iodine alone may be effective; however, further studies are required to assess this.
Other agents under investigation include ganciclovir 0.15% gel.
Herpes zoster ophthalmicus (varicella zoster virus)
Antivirals acting on posterior segment viral infections
CMV retinitis
Systemic treatments
All systemic treatment must be administered in partnership with an HIV or infectious disease physician.
Oral valganciclovir is effective and easily administered.20 However, it is expensive and not always available. Care must be taken to monitor renal function and full blood counts.
Alternative systemic treatments include systemic intravenous ganciclovir (Table 5).
Foscarnet21 is very rarely used now because of the advent of highly active antiretroviral therapy (HAART) and the need for daily two-hour infusions via indwelling catheter.
Intravitreal treatment
Intravitreal ganciclovir injection is a very useful option as it can be done as an outpatient and gives high levels of concentration of the drug where it is needed. However, it does not protect the other eye or protect against systemic CMV. It should be given as adjuvant therapy if there is infection within 1 disc diameter of the fovea or optic disc.
Table 5 Antiviral treatment options for CMV retinitis
| Drug | Dose / regimen | Comments and evidence for use |
|---|---|---|
| Systemic oral valganciclovir | Induction dose: 900 mg orally twice a day for 14–21 days, followed by maintenance dose of 900 mg orally once a day until CD4 count normalises | Need to monitor full blood count and renal function due to potential bone marrow suppression and renal toxicity; expensive As effective as intravenous ganciclovir for induction and long-term therapy for CMV retinitis in HIV patients20 |
| Systemic intravenous ganciclovir | Induction dose: 5 mg/kg/dose every twelve hours for 1–21 days, followed by a maintenance dose of 5 mg/kg once a day until CD4 count normalises | Need to monitor full blood count and renal function due to potential bone marrow suppression and renal toxicity. Requires hospital attendance/ admission for intravenous administration. First generation antiviral; effective22 |
| Intravitreal ganciclovir | 2.5 mg in 0.1 ml once a week | An alternative if systemic valganciclovir or ganciclovir is not available or too expensive.23 All patients who have infection within 1-disc diameter of the fovea or optic disc should receive intravitreal injections. Inexpensive, can be given as an outpatient. Risk of endophthalmitis following intravitreal injection. |
Acute retinal necrosis, progressive outer retinal necrosis
Although acute retinal necrosis (ARN) and progressive outer retinal necrosis (PORN) are different clinical entities (ARN affecting immunocompetent individuals and PORN affecting immunocompromised individuals). Both are caused by varicella zoster virus and, to a lesser extent, by HSV-1 and HSV-2.
The antivirals used to treat ARN and PORN are similar. The treatment options are:
- Initially, intravenous aciclovir (10 mg/kg three times a day) for 5 –10 days, then oral aciclovir (800 mg five times a day) for 4–6 weeks
- Valaciclovir 2 g four times a day for 7–10 days, then oral valaciclovir 1 g three times a day for six weeks; this option can be given as an outpatient.
Either of these options can be combined with intravitreal foscarnet 2.4 mg (if available) which has been shown to reduce the risk of retinal detachment and hastens viral inactivity.24
References
1 Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. BiochimBiophys Acta. 1959 Mar;32(1):295–6.
2. Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2’- deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol. 1962 Aug;68(2):235–9.
3 Jones BR, Coster DJ, Fison PN, Thompson GM, Cobo LM, Falcon MG. Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers. Lancet. 1979 Feb 3;1(8110):243–4.
4 Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2015 Jan 9;1:CD002898.
5 Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 2016 Dec;29(6):654–62.
6 Collum LM, McGettrick P, Akhtar J, Lavin J, Rees PJ. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol. 1986 Jun;70(6):435–8.
7 Hoh HB, Hurley C, Claoue C, Viswalingham M, Easty DL, Goldschmidt P, et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol. 1996 Feb;80(2):140–3.
8 Høvding G. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. Acta Ophthalmol. 1989 Feb;67(1):51–4.
9 Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994 Dec;101(12):1883–95–discussion1895–6.
10 Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994 Dec;101(12):1871–82.
11 A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. Arch Ophthalmol. 1996 Sep;114(9):1065–72.
12 Wilhelmus KR, Beck RW, Moke PS, Dawson CR, Barron BA, Jones DB, et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998 Jul 30;339(5):300–6.
13 Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother. 2014 Jan;15(1):61–71.
14 Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986 Jun;93(6):763–70.
15 Neoh C, Harding SP, Saunders D, Wallis S, Tullo AB, Nylander A, et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye. 1994;8 ( Pt 6)(6):688–91.
16 Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546–53.
17 Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15;123(2):89–96.
18 Pepose JS, Ahuja A, Liu W, Narvekar A, Haque R. Randomized, Controlled, Phase 2 Trial of Povidone- Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2019 Sep;205:197.
19 Ramakrishnan S, Vempati J, Baskaran P. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/ Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2019 Aug;204:140.
20 Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002 Apr 11;346(15):1119–26.
21 Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992 Jan 23;326(4):213–20.
22 Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993 Sep;168(3):557–63.
23 Miao H, Tao Y, Jiang Y-R, Li X-X. Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation. Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1829–33.
24 Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya PM, Yeh S, MD SJB, et al. Diagnosis and Treatment of Acute Retinal Necrosis A Report by the American Academy of Ophthalmology. Ophthalmology. 2017 Mar 1;124(3):382–92.